Hardwick,, United Kingdom Clinical Trials
A listing of Hardwick,, United Kingdom clinical trials actively recruiting patients volunteers.
Found 175 clinical trials
NTLA-2002 in Adults With Hereditary Angioedema (HAE) (NTLA-2002)
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
- 0 views
- 26 Jul, 2022
- +2 other locations
Functional and Ultrasound Guided Resection of Glioblastoma (FUTURE-GB)
Functional and ultrasound-guided resection of glioblastoma: assessing the use of additional imaging during surgery to improve outcomes for patients with glioblastoma brain tumours
- 0 views
- 18 Jun, 2022
- +16 other locations
DAYBREAK: Phase 2 Study in Patients With Specific Gene Defects in the MC4R Pathway
2 stage (open-label run-in, followed by randomized, double-blind, placebo-controlled withdrawal), study trial of setmelanotide in patients with obesity and specific gene defects variants in the melanocortin-4 receptor (MC4R) pathway.
- 0 views
- 13 Jul, 2022
- +13 other locations
A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy in advanced solid tumours that have progressed following SoC treatment.
- 0 views
- 13 May, 2022
- +9 other locations
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) (ENRICH-AF)
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation (CHA2DS2-VASc 2) patients with previous intracranial hemorrhage.
- 15 views
- 16 Feb, 2022
- +139 other locations
Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer
The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development. Eligible patients will …
- 23 views
- 26 May, 2022
- +28 other locations
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T). There are two phases to this study: the Parent Study, and the Extension Phase. The Parent Study evaluates the safety and efficacy of …
- 2 views
- 18 Feb, 2022
- +4 other locations
OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial (OPTIMAS)
OPTIMAS is a large, prospective, partially blinded randomised controlled trial of early (within 4 days [96hrs]) or standard (between day 7 and day 14 after stroke onset) initiation of anticoagulation after stroke in patients with atrial fibrillation (AF), using any licensed dose of a direct oral anticoagulant (DOAC). The trial …
- 76 views
- 20 Feb, 2022
- +43 other locations
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several …
- 73 views
- 15 Jun, 2022
- +60 other locations
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation (NOTUS)
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on Pre-bronchodilator …
- 314 views
- 02 Jul, 2022
- +319 other locations